drugset / Trial / NCT02454348

NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock

NCT02454348

Phase 4 Withdrawn University of Arkansas
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Sepsis, a systemic host response to the invasion of a pathogenic microorganism, may progress to severe sepsis, wherein the patient experiences acute dysfunction in at least one organ system, and further develop into septic shock if the patient cannot regain adequate systemic blood pressure and perfusion after adequate and appropriate fluid resuscitation. Further prospective study of the potential mortality benefit with combination norepinephrine and vasopressin in critically ill patients with septic shock needs to be performed. Our research will resolve this essential question and improve the scientific knowledge surrounding vasoactive medications in patients with septic shock.

Timeline

Start
2015-11-01
Primary completion
2017-11-27
Completion
2017-11-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Norepinephrine Other / unclassified 0.05 ug/kg Other
Comparator Norepinephrine Other / unclassified 0.5 ug/kg Other
Comparator Vasopressin Peptide 0.04 iu Other

Indications

No indication recorded.